Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...96979899100101102103104105106...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. (Pubmed Central) -  Sep 16, 2020   
    For this reason, lenvatinib is strongly considered a causative drug for gallbladder perforation. Liver function and PVTT are useful for stratifying prognosis of HCC patients treated with TKI, the applicative classification may lead to appropriate therapy and better prognosis.
  • ||||||||||  lenvatinib / Generic mfg.
    [VIRTUAL] Chest Wall Metastasis as the First Clinical Manifestation of Hepatocellular Carcinoma: A Rare Case Report () -  Sep 15, 2020 - Abstract #ACG2020ACG_2991;    
    Consequently, he received localized spine and left chest wall radiotherapy, and upon completion, he was discharged home, and currently, he is on systemic chemotherapy with Lenvatinib...Timely recognition of risk factors can prevent and aid early diagnosis of such aggressive tumors. Chest Wall Metastasis MRI Abdomen showing the Primary Liver Lesion Pathology Slide: H & E stain showing features suggestive of HCC on a liver biopsy
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    [VIRTUAL] An Unusual Cause of Upper Gastrointestinal Bleeding in a Patient With Cirrhosis () -  Sep 15, 2020 - Abstract #ACG2020ACG_2004;    
    Surgical removal can be considered in patients with sufficient liver function and good performance status. Other options include local therapies such as TACE, and systemic therapy such as sorafenib/lenvatinib, which are tyrosine kinase inhibitors that reduce angiogenesis and increases apoptosis of HCC cells.
  • ||||||||||  cisplatin / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD), gemcitabine / Generic mfg.
    Clinical, Journal:  Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report. (Pubmed Central) -  Sep 10, 2020   
    The patient was treated with three courses of combination chemotherapy, which included gemcitabine (1000 mg/m) and cisplatin (25 mg/m), as well as S-1 (120 mg/day) for adjuvant chemotherapy...Thereafter, the patient was prescribed the molecularly targeted drug, lenvatinib (12 mg/day)...The patient died 5 months after the operation. We experienced a case of primary undifferentiated carcinoma with osteoclast-like giant cells in the liver showed rapidly developing multiple metastases after curative liver resection.
  • ||||||||||  Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Trial primary completion date, Metastases:  Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (clinicaltrials.gov) -  Sep 9, 2020   
    P2,  N=6, Active, not recruiting, 
    We experienced a case of primary undifferentiated carcinoma with osteoclast-like giant cells in the liver showed rapidly developing multiple metastases after curative liver resection. Trial primary completion date: Dec 2020 --> Nov 2019
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Metastases:  EPOC1706: Lenvatinib and Pembrolizumab Simultaneous Combination Study (clinicaltrials.gov) -  Sep 9, 2020   
    P2,  N=29, Active, not recruiting, 
    Trial primary completion date: Dec 2020 --> Nov 2019 Trial completion date: Mar 2022 --> Sep 2022
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Targeting angiogenesis for liver cancer: Past, present, and future. (Pubmed Central) -  Sep 5, 2020   
    Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma. (clinicaltrials.gov) -  Sep 2, 2020   
    P=N/A,  N=170, Recruiting, 
    Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, P2 data, Journal:  A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. (Pubmed Central) -  Sep 2, 2020   
    P2
    Not yet recruiting --> Recruiting Lenvatinib demonstrated activity in patients with RET fusion-positive lung adenocarcinomas; although the response rate was relatively low, the median PFS supports the activity of lenvatinib in these patients.
  • ||||||||||  E7386 / Eisai, PRISM Pharma
    Trial completion date, Trial primary completion date:  E7386-J081-102: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (clinicaltrials.gov) -  Aug 30, 2020   
    P1b,  N=42, Recruiting, 
    Urinalysis by combination of the dipstick test and UPCR assessment might be a better strategy for preventing unnecessary interruption of lenvatinib. Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Aug 30, 2020   
    P=N/A,  N=500, Active, not recruiting, 
    Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022 Enrolling by invitation --> Active, not recruiting | Trial completion date: May 2023 --> Feb 2022 | Trial primary completion date: May 2023 --> Feb 2022